Department of Biological Sciences, Seton Hall University, South Orange, NJ, USA.
Vaccine. 2020 Jul 31;38(35):5634-5646. doi: 10.1016/j.vaccine.2020.06.067. Epub 2020 Jul 7.
Streptococcus pneumoniae (Spn) remains a considerable threat to public health despite the availability of antibiotics and polysaccharide conjugate vaccines. The lack of mucosal immunity in addition to capsular polysaccharide diversity, has proved to be problematic in developing a universal vaccine against Spn. Targeting antigen to Fc receptors is an attractive way to augment both innate and adaptive immunity against mucosal pathogens, by promoting interactions with activating Fcγ receptors (FcγR) that mediate diverse immunomodulatory functions. The effect of targeting FcγR is highly influenced by the IgG subclass, which bares differential affinities for activating and inhibitory FcγR. In the current study we demonstrate targeting activating FcγR with fusion proteins consisting of PspA and IgG2a Fc enhance PspA-specific immune responses, and effectively protect against mucosal Spn challenge. Specifically, targeting PspA to FcγR polarized alveolar macrophage to the AM1 phenotype and increased conventional dendritic cell subsets in the lung in addition to augmenting Th1 cytokines and PspA-specific IgG and IgA. In contrast, fusion proteins consisting of PspA fused to the IgG1 Fc provided minimal benefit over administration of PspA alone, as a result of interaction with the inhibitory FcγRIIB. Protective efficacy of the IgG1 fusion protein was significantly enhanced in animals deficient for FcγRIIB accompanied by increased B cell maturation and proliferation levels in these animals. These studies demonstrate FcγR targeting is an effective strategy for inducing potent cellular and humoral responses via mucosal immunization with Fc fusion proteins, however, careful consideration of the Fc region utilized is required since Fc isotype subclass heavily influenced immunization induced effector functions and survival against lethal Spn challenge. Fc-engineering with specific attention to FcγRIIB engagement presents a valuable vaccine strategy for protecting against Spn infection.
肺炎链球菌 (Spn) 尽管有抗生素和多糖结合疫苗可用,但仍然对公共卫生构成重大威胁。除了荚膜多糖多样性之外,缺乏粘膜免疫已被证明是开发针对 Spn 的通用疫苗的一个问题。将抗原靶向 Fc 受体是增强针对粘膜病原体的先天和适应性免疫的一种有吸引力的方法,通过促进与介导多种免疫调节功能的激活 Fcγ 受体 (FcγR) 的相互作用来实现。靶向 FcγR 的效果受 IgG 亚类的强烈影响,该亚类对激活和抑制性 FcγR 具有不同的亲和力。在目前的研究中,我们证明了用由 PspA 和 IgG2a Fc 组成的融合蛋白靶向激活 FcγR 可增强 PspA 特异性免疫反应,并有效预防粘膜 Spn 感染。具体而言,将 PspA 靶向 FcγR 可将肺泡巨噬细胞极化到 AM1 表型,并增加肺部的常规树突状细胞亚群,同时还可增强 Th1 细胞因子和 PspA 特异性 IgG 和 IgA。相比之下,由 PspA 融合到 IgG1 Fc 组成的融合蛋白与抑制性 FcγRIIB 相互作用,提供的益处很小,与单独给予 PspA 相比。FcγRIIB 缺陷动物的 IgG1 融合蛋白的保护效力显著增强,这些动物的 B 细胞成熟和增殖水平也增加。这些研究表明,通过粘膜免疫用 Fc 融合蛋白靶向 FcγR 是一种有效的诱导强大细胞和体液反应的策略,但是,由于 Fc 同种型亚类强烈影响免疫诱导的效应功能和对致死性 Spn 感染的生存能力,因此需要仔细考虑所使用的 Fc 区。特别注意 FcγRIIB 结合的 Fc 工程提出了一种有价值的疫苗策略,可用于预防 Spn 感染。